[
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Monday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=53fd828b2c6f3707c3c056058d136448f0c253109af69169e50845405f530f91",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738600500,
      "headline": "Pfizer Inc. stock underperforms Monday when compared to competitors",
      "id": 132546264,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=53fd828b2c6f3707c3c056058d136448f0c253109af69169e50845405f530f91"
    }
  },
  {
    "ts": null,
    "headline": "Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer",
    "summary": "Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as a Hold.",
    "url": "https://finnhub.io/api/news?id=e4abf5d97248362d4bf4b8c45f8b0ea64719b1565669693b05391cdf74b95596",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738574100,
      "headline": "Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer",
      "id": 132521902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039103939/image_2039103939.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as a Hold.",
      "url": "https://finnhub.io/api/news?id=e4abf5d97248362d4bf4b8c45f8b0ea64719b1565669693b05391cdf74b95596"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: positive results in colorectal cancer",
    "summary": "Pfizer announced Monday the publication of positive results from a phase 3 study evaluating its small molecule Braftovi in the treatment of patients with metastatic colorectal cancer.The study showed...",
    "url": "https://finnhub.io/api/news?id=3d4db5b97a1e46b2c84dcb4a9770f5c7692b8cade27570138f5871844426caa3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738571775,
      "headline": "Pfizer: positive results in colorectal cancer",
      "id": 132520336,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announced Monday the publication of positive results from a phase 3 study evaluating its small molecule Braftovi in the treatment of patients with metastatic colorectal cancer.The study showed...",
      "url": "https://finnhub.io/api/news?id=3d4db5b97a1e46b2c84dcb4a9770f5c7692b8cade27570138f5871844426caa3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial",
    "summary": "BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic...",
    "url": "https://finnhub.io/api/news?id=23dfa2f9b148897dc980feab38fbb16aec88d677fa7f8a5940440077739a33f3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738565164,
      "headline": "Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial",
      "id": 132519688,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic...",
      "url": "https://finnhub.io/api/news?id=23dfa2f9b148897dc980feab38fbb16aec88d677fa7f8a5940440077739a33f3"
    }
  },
  {
    "ts": null,
    "headline": "Smaller US winter COVID wave adds pressure to Pfizer turnaround",
    "summary": "Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID...",
    "url": "https://finnhub.io/api/news?id=6368bc1f330a123b867bf8e2baab75373833a59e727b2cc94f5968813b853305",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738562596,
      "headline": "Smaller US winter COVID wave adds pressure to Pfizer turnaround",
      "id": 132519467,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID...",
      "url": "https://finnhub.io/api/news?id=6368bc1f330a123b867bf8e2baab75373833a59e727b2cc94f5968813b853305"
    }
  }
]